Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A | 0.720 | CausalMutation | CLINVAR | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. | 23414587 | 2013 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. | 23414587 | 2013 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. | 23414587 | 2013 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. | 23614898 | 2013 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. | 20179705 | 2010 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | 20130576 | 2010 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. | 20179705 | 2010 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | 20130576 | 2010 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. | 20179705 | 2010 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. | 20130576 | 2010 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. | 18390968 | 2008 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | Distinct sets of genetic alterations in melanoma. | 16291983 | 2005 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | Distinct sets of genetic alterations in melanoma. | 16291983 | 2005 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | Distinct sets of genetic alterations in melanoma. | 16291983 | 2005 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | Ras mutations in human melanoma: a marker of malignant progression. | 8120410 | 1994 |
|||||||
|
|
A | 0.720 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 |
|||||||
|
|
G | 0.720 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 |
|||||||
|
|
T | 0.720 | CausalMutation | CLINVAR | N-ras mutations in human cutaneous melanoma from sun-exposed body sites. | 2674680 | 1989 |